News
Eli Lilly › Great businesses have a habit of remaining so even when market volatility arises. The stock market is cyclical, ...
According to Lokant, if you have COVID and notice certain concerning symptoms, such as difficulty breathing, chest pain or ...
Hospitalists working in behavioral health centers face unique challenges, including limited resources and complex patient ...
The interview with Dr Asad Khan on long Covid (Solidarity 747-748) highlights the contribution to the growth in mental ill-health of widespread long Covid, which affects hundreds of millions of ...
4d
24/7 Wall St. on MSN4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return PotentialHere are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.
Bay Area researchers created a group of AI “scientists” that proposed a potential COVID treatment. They say the approach ...
2d
MedPage Today on MSNNovel Drug May Help Speed Kids' GI Recovery in Severe Post-COVID SyndromeYonker is a co-inventor on a patent for zonulin antagonists to treat MIS-C, as are two other co-authors. Co-authors also ...
In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more ...
2d
Verywell Health on MSNWhat to Know About COVID Vaccine This FallThere have been lots of changes to COVID vaccine recommendations. Here is the current vaccine schedule for people 6 months to 65+ years old.
Janus kinase (JAK) inhibitors are associated with decreased mortality and fewer serious adverse events among adults hospitalized with COVID-19.
Larazotide, a therapy known to treat celiac disease, shows promise as a safe treatment for multisystem inflammatory syndrome in children linked to COVID-19, enhancing recovery and symptom resolution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results